Literature DB >> 10834863

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Y Yoshihara1, H Nakamura, K Obata, H Yamada, T Hayakawa, K Fujikawa, Y Okada.   

Abstract

OBJECTIVE: Matrix metalloproteinases (MMPs) are expressed in joint tissues of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). The objective of this study was to define the steady state levels of seven different MMPs and two tissue inhibitors of metalloproteinases (TIMPs) as well as the potential metalloproteinase activity in the synovial fluid (SF) to provide more insight into the role of MMPs in cartilage destruction in RA and OA.
METHODS: Levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, TIMP-1, and TIMP-2 in SF aspirated from knee joints of 97 patients with RA and 103 patients with OA were measured by the corresponding one step sandwich enzyme immunoassays. Proteolytic activity of MMPs in these SFs was examined in an assay using [(3)H]carboxymethylated transferrin substrate in the presence of inhibitors of serine and cysteine proteinases after activation with p-aminophenylmercuric acetate (APMA). Destruction of RA knee joints was radiographically evaluated.
RESULTS: Levels of MMP-1, MMP-2, MMP-3, MMP-8, and MMP-9 were significantly higher in RA SF than in OA SF. MMP-7 and MMP-13 were detectable in more than 45% of RA SFs and in less than 20% of OA SFs, respectively. Among the MMPs examined, MMP-3 levels were extremely high compared with those of other MMPs. Direct correlations were seen between the levels of MMP-1 and MMP-3 and between those of MMP-8 and MMP-9 in RA SF. Although the levels of MMP-1 and MMP-3 increased even in the early stage of RA, those of MMP-8 and MMP-9 were low in the early stage and increased with the progression of RA. Molar ratios of the total amounts of the MMPs to those of the TIMPs were 5.2-fold higher in patients with RA than in OA, which was significant. APMA-activated metalloproteinase activity in SF showed a similar result, and a direct correlation was seen between the molar ratios and the activity in RA SF.
CONCLUSIONS: Our results show that high levels of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, and TIMP-1 are present in RA SF and suggest that once these MMPs are fully activated, they have an imbalance against TIMPs, which may contribute to the cartilage destruction in RA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834863      PMCID: PMC1753174          DOI: 10.1136/ard.59.6.455

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  55 in total

1.  A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization.

Authors:  Y Okada; H Nagase; E D Harris
Journal:  J Biol Chem       Date:  1986-10-25       Impact factor: 5.157

2.  Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.

Authors:  A Larsen; K Dale; M Eek
Journal:  Acta Radiol Diagn (Stockh)       Date:  1977-07

3.  Coordinate regulation of stromelysin and collagenase genes determined with cDNA probes.

Authors:  S M Frisch; E J Clark; Z Werb
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

4.  Platelet-derived collagenase inhibitor: characterization and subcellular localization.

Authors:  T W Cooper; A Z Eisen; G P Stricklin; H G Welgus
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Paired serum and synovial fluid values of alpha 2-macroglobulin and TIMP in rheumatoid arthritis.

Authors:  T E Cawston; P McLaughlin; B L Hazleman
Journal:  Br J Rheumatol       Date:  1987-10

6.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.

Authors:  R Altman; E Asch; D Bloch; G Bole; D Borenstein; K Brandt; W Christy; T D Cooke; R Greenwald; M Hochberg
Journal:  Arthritis Rheum       Date:  1986-08

7.  Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis.

Authors:  Y Okada; N Takeuchi; K Tomita; I Nakanishi; H Nagase
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

8.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

9.  Stimulation of procollagenase synthesis parallels increases in cellular procollagenase mRNA in human articular chondrocytes exposed to recombinant interleukin 1 beta or phorbol ester.

Authors:  M L Stephenson; M B Goldring; J R Birkhead; S M Krane; H J Rahmsdorf; P Angel
Journal:  Biochem Biophys Res Commun       Date:  1987-04-29       Impact factor: 3.575

10.  Platelets in the synovial fluid of patients with rheumatoid arthritis.

Authors:  M Farr; A Wainwright; M Salmon; C A Hollywell; P A Bacon
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

View more
  159 in total

1.  Matrix metalloproteinase-9 and -2 expression in the olfactory bulb following methyl bromide gas exposure.

Authors:  Stephen R Bakos; James E Schwob; Richard M Costanzo
Journal:  Chem Senses       Date:  2010-06-07       Impact factor: 3.160

2.  The effect of local anaesthetics on synoviocytes: a possible indirect mechanism of chondrolysis.

Authors:  Hillary J Braun; Benjamin T Busfield; Hyeon Joo Kim; Gaetano J Scuderi; Jason L Dragoo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-06-21       Impact factor: 4.342

Review 3.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

4.  Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.

Authors:  N J Peake; H E Foster; K Khawaja; T E Cawston; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

5.  Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?

Authors:  Salih Pay; Hakan Erdem; Aysel Pekel; Ismail Simsek; Ugur Musabak; Ali Sengul; Ayhan Dinc
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

6.  Correlations between biochemical markers in the synovial fluid and severity of rotator cuff disease.

Authors:  M S Tajana; L Murena; F Valli; A Passi; F A Grassi
Journal:  Chir Organi Mov       Date:  2009-04

Review 7.  The roles of catabolic factors in the development of osteoarthritis.

Authors:  Dominick J Blasioli; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2013-12-11       Impact factor: 6.389

8.  Regulation of matrix metalloproteinase expression by dynamic tensile strain in rat fibrochondrocytes.

Authors:  J Deschner; B Rath-Deschner; S Agarwal
Journal:  Osteoarthritis Cartilage       Date:  2005-11-14       Impact factor: 6.576

9.  The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation.

Authors:  Matthew T Hardison; F Shawn Galin; Christopher E Calderon; Uros V Djekic; Suzanne B Parker; Keith M Wille; Patricia L Jackson; Robert A Oster; K Randall Young; J Edwin Blalock; Amit Gaggar
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis.

Authors:  Shilpi Agarwal; Ramnath Misra; Amita Aggarwal
Journal:  Rheumatol Int       Date:  2008-12-04       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.